Neurizon Therapeutics (ASX: NUZ) said it developed a new oral liquid formulation of its drug candidate NUZ-001 for the treatment of amyotrophic lateral sclerosis, according to a Friday Australian bourse filing.

The firm said the treatment was developed in direct response to feedback from patients and carers. It is designed to support patients with all stages of the disease, particularly those with swallowing difficulties such as bulbar onset.

The firm is integrating the formulation into its ongoing clinical development program for NUZ-001, and it will be evaluated for bioequivalence and patient acceptability alongside the standard tablet form. The human bioequivalence study is scheduled to commence in the first half of 2026.

The firm's shares fell 3% on market close.